

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司 \***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1548)**

## **GRANT OF RESTRICTED SHARES AND SUPPLEMENTAL ANNOUNCEMENT ON THE AMENDMENT TO THE 2021 RESTRICTED SHARE AWARD SCHEME**

### **THE 2021 RESTRICTED SHARE AWARD SCHEME**

Reference is made to the announcements of the Company in relation to the adoption and principal terms of the restricted share award scheme dated 24 August 2021 (the “**Adoption Announcement**”) and the amendment thereto dated 26 May 2022 (the “**Amendment Announcement**”) (collectively, the “**Announcements**”) (the “**RSA Scheme 2021**”). Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as defined in the Announcements.

As stated in the Adoption Announcement, the purposes and objectives of the RSA Scheme 2021 are to (i) provide the Selected Participants with the opportunity to acquire proprietary interests in the Company, (ii) encourage the Selected Participants to work towards enhancing the value of the Company and its Shares or the benefit of the Company and its Shareholders as a whole, and (iii) provide the Company with a flexible means of either retaining, incentivizing, rewarding, remunerating, compensating and/or providing benefits to the Selected Participants (the “**Objectives**”).

The amendment to the RSA Scheme 2021 by expanding the definition of “Eligible Participant(s)” and including “any person or entity who has made significant contribution, or will potentially make significant contribution to, the development of the Group”, in addition to “any director or an employee of the Company or any of its subsidiaries”, meets the Objectives.

The Company believes that by providing a grant of share awards to any person or entity who has made significant contribution, or will potentially make significant contribution to, the development of the Group an opportunity to acquire a proprietary interest in the Group, it can (i) align the interests of such person(s) or entity(ies) directly to that of the Shareholders, and (ii) motivate them by providing a direct economic interest to such person(s) or entity(ies) in striving for the future growth and development of and increasing the value of the Group in the long run. Such person(s) or entity(ies) could include consultants, advisers, suppliers, and/or agents. By fulfilling (i) and (ii) above, the Company is of the view that the Objectives could be achieved.

The Board will carefully consider and select Selected Participants who have contributed or will potentially make significant contribution to the development of the Group in the areas of, including without limitation, corporate management enhancement, operational improvement, technical and innovation advancement, and business development and investment.

## **GRANT OF RESTRICTED SHARES PURSUANT TO THE RSA SCHEME 2021**

The board (the “**Board**”) of directors (the “**Directors**”) of Genscript Biotech Corporation (the “**Company**”) announces on 2 September 2022 that the Company has resolved to make grants of restricted shares under the RSA Scheme 2021.

The Board is pleased to announce that on 2 September 2022, selected grantees (the “**RSA Grantee(s)**”) were granted 255,390 Restricted Shares (the “**RSA Shares**”), subject to acceptance of the RSA Grantees, pursuant to the RSA Scheme 2021 (the “**RSA Grant**”). Details of the RSA Grant are set out as follows:

Number of RSA Shares:	255,390 Restricted Shares, representing approximately 0.01208% of the issued share capital of the Company as at the date of this announcement
RSA Grantees:	Employees of the Company
Date of Grant:	2 September 2022
Market price of the Shares:	The closing price per Share on the Stock Exchange on the date of grant of the Restricted Shares is HK\$23.7 per Share
Vesting Period of the RSA Shares:	The RSA Shares will be vested in two or three batches, and that the last batch of the RSA Shares will be vested on 2 September 2025

The vesting conditions of certain RSA Shares include without limitation, (i) the RSA Grantees having met their respective key performance criteria, and/or (ii) the Company’s annual revenue growth rate having been achieved. The Board is entitled to waive certain vesting conditions at its own discretion under specified circumstances as specified at the time of making the grant.

To the best knowledge of the Directors, none of the RSA Grantees is a Director, chief executive or substantial shareholder (as defined in the Listing Rules) of the Company or associate (as defined in the Listing Rules) of any of them.

The Company will issue and allot 255,390 RSA Shares to the Trustee or the nominee account of the Company (of which the beneficial owner will be the relevant RSA Grantees) under the general mandate granted by the shareholders of the Company on 27 May 2022 and in accordance with the terms of the RSA Scheme 2021. The new Shares so issued will be held on trust for certain RSA Grantees until the end of each vesting period which may differ among the RSA Grantees and be transferred to the RSA Grantees upon satisfaction of the relevant vesting conditions as may be specified by the Board at the time of making the RSA Grant.

The new Shares to be issued and allotted by the Company to the Trustee or the nominee account of the Company represent approximately 0.01208% of the Company's issued share capital as at the date of this announcement and approximately 0.01208% of the Company's enlarged issued share capital after the issue and allotment. To the best knowledge of the Directors, the Trustee and its ultimate beneficial owners and all of the RSA Grantees are third parties independent of the Company and are not connected persons of the Company, and none of them is a Director, chief executive or substantial shareholder (as defined under the Listing Rules) of the Company or associate (as defined under the Listing Rules) or any of them as at the time of granting the RSA Shares.

The new Shares, when issued and fully paid, will rank pari passu among themselves and with the other Shares in issue, with the right to receive all dividends and other distributions declared, made or paid on or after the date of issue and allotment. Pursuant to the RSA Scheme 2021, the Trustee shall not exercise the voting rights in respect of any Shares held by it under trust. Application will be made by the Company to the Listing Committee of the Stock Exchange for the grant of approval for the listing of, and permission to deal in, the 255,390 new Shares to be issued and allotted.

By order of the Board  
**Genscript Biotech Corporation**  
**Meng Jiange**  
*Chairman and Executive Director*

Hong Kong, 2 September 2022

*As at the date of this announcement, the executive Directors are Mr. Meng Jiange, Ms. Wang Ye and Dr. Zhu Li; the non-executive Directors are Dr. Zhang Fangliang, Dr. Wang Luquan, Mr. Pan Yuexin and Ms. Wang Jiafen; and the independent non-executive Directors are Mr. Guo Hongxin, Mr. Dai Zumian, Mr. Pan Jiuan and Dr. Wang Xuehai.*

\* For identification purposes only